Shares of Lupin Limited are in focus today after the global pharmaceutical major announced a significant licensing and supply agreement aimed at strengthening its presence in the fast-growing diabetes and obesity treatment market.
Lupin, through its wholly owned subsidiary Lupin Atlantis Holdings SA (LAHSA), has entered into a licensing and supply agreement with Galenicum Health, S.L.U. for finished formulations of injectable Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. The development is seen as a strategic move that enhances Lupin’s international footprint in complex injectables and chronic therapy segments.
Under the terms of the agreement, Galenicum Health will be responsible for the development, manufacturing, and supply of the injectable Semaglutide formulations. Lupin, on the other hand, will manage regulatory submissions, secure necessary approvals, and lead commercialization and distribution across 23 global markets. These markets include key regions such as Canada, Europe, Southeast Asia, and Latin America, significantly expanding Lupin’s reach beyond India.
Semaglutide is a widely used GLP-1 receptor agonist that plays a crucial role in regulating blood sugar levels and appetite. It is primarily prescribed for adults with Type 2 diabetes, in combination with diet and exercise, and has also gained strong traction for long-term weight management in adults with obesity or overweight conditions. Global demand for GLP-1–based therapies has surged in recent years due to rising diabetes prevalence and increasing focus on obesity management.
